-
ASH 2024 | Dr. Shanshan Pei : First Discovery of TFG-ROS1 as a Rare Driver Gene in Myeloid Leukemia with Promising ALK/ROS1 Inhibitor Efficacy
From December 7 to 10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, bringing together leading experts to discuss pivotal advances in hematology. Among the highlights was a groundbreaking study by Dr. Shanshan Pei and his team from The First Affiliated Hospital,Zhejiang University and Liangzhu Laboratory. This…
-
ASH 2024 | Dr. Bing Han: Advances in Aplastic Anemia and PNH Treatment – Highlights from EBMT-SAAWP Studies
From December 7 to 10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, USA. Experts and scholars from around the globe gathered to discuss and exchange insights on the latest research in hematology. During the conference, Dr. Bing Han from Peking Union Medical College provided an…
-
Unlocking the Role of the Gut Microbiome in Colorectal Cancer: Insights and Future Directions
The Influence of Gut Microbiota on CRC Risk The gut microbiome plays a critical role in colorectal cancer (CRC) development, prognosis, and treatment response. Dr. Andrew T. Chan’s presentation at…
-
Treatment for Advanced Esophagogastric Cancer: Insights from Recent Clinical Trials and Emerging Therapies
KEYNOTE-811: PD-1 Inhibition in Advanced EGC KEYNOTE-811 investigated the efficacy of pembrolizumab (PD-1 inhibitor) in combination with chemotherapy for the first-line (1L) treatment of unresectable, advanced, or metastatic EGC. The…
-
Annual Review | Dr. Jun Guo: Advances in Systemic Therapy for Melanoma in 2024
Malignant melanocytes can appear in various tissues throughout the body, most commonly in the skin and mucous membranes, and are highly aggressive. With continuous advancements in targeted therapy, immunotherapy, and biological therapy, even advanced melanoma can, in many cases, be managed as a chronic disease. Looking back at 2024, what were the key research developments…
-
ESMO Asia China Voice | Dr. Zhi Peng Interprets DESTINY-Gastric06: ADC Therapy Unveils a New Era for Advanced HER2-Positive Gastric Cancer Treatment
________________________________________ Oncology Frontier: You presented the findings of the DESTINY-Gastric06 study at the congress. Could you introduce the background of the study and its key results? Dr. Zhi Peng: The…
-
ASCO GI 2025 | Dr. Rongbo Lin: SYLT-026 Study Marks a Breakthrough in Immunotherapy for MSS-Type Colorectal Cancer
Microsatellite stable (MSS) and mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCRC) has shown minimal response to immune checkpoint inhibitors as monotherapy, making combination immunotherapy a key strategy to address this clinical challenge. At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), a multicenter phase II study led by Dr. Rongbo…
-
ASCO GI 2025 | Dr. Lin Shen & Dr. Zhi Peng: PD-L1/TGF-βRII Bispecific Antibody SHR-1701 Improves Efficacy and Protects Bone Marrow in First-Line Treatment of G/GEJA
From January 23 to 25, 2025, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) was held in San Francisco, showcasing significant advancements in gastrointestinal cancer treatment. The Peking University Cancer Hospital presented a series of cutting-edge findings, contributing to global progress in digestive tract oncology. On the first day of the conference,…
Connecting Medical Expertise through Media